You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Hilton T, Sanborn R, Boulmay B, et al
Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC
Journal for ImmunoTherapy of Cancer 2014;2:P249. doi: 10.1186/2051-1426-2-S3-P249